跳转至内容
Merck
  • Aerobic exercise training prevents heart failure-induced skeletal muscle atrophy by anti-catabolic, but not anabolic actions.

Aerobic exercise training prevents heart failure-induced skeletal muscle atrophy by anti-catabolic, but not anabolic actions.

PloS one (2014-10-21)
Rodrigo W A Souza, Warlen P Piedade, Luana C Soares, Paula A T Souza, Andreo F Aguiar, Ivan J Vechetti-Júnior, Dijon H S Campos, Ana A H Fernandes, Katashi Okoshi, Robson F Carvalho, Antonio C Cicogna, Maeli Dal-Pai-Silva
摘要

Heart failure (HF) is associated with cachexia and consequent exercise intolerance. Given the beneficial effects of aerobic exercise training (ET) in HF, the aim of this study was to determine if the ET performed during the transition from cardiac dysfunction to HF would alter the expression of anabolic and catabolic factors, thus preventing skeletal muscle wasting. We employed ascending aortic stenosis (AS) inducing HF in Wistar male rats. Controls were sham-operated animals. At 18 weeks after surgery, rats with cardiac dysfunction were randomized to 10 weeks of aerobic ET (AS-ET) or to an untrained group (AS-UN). At 28 weeks, the AS-UN group presented HF signs in conjunction with high TNF-α serum levels; soleus and plantaris muscle atrophy; and an increase in the expression of TNF-α, NFκB (p65), MAFbx, MuRF1, FoxO1, and myostatin catabolic factors. However, in the AS-ET group, the deterioration of cardiac function was prevented, as well as muscle wasting, and the atrophy promoters were decreased. Interestingly, changes in anabolic factor expression (IGF-I, AKT, and mTOR) were not observed. Nevertheless, in the plantaris muscle, ET maintained high PGC1α levels. Thus, the ET capability to attenuate cardiac function during the transition from cardiac dysfunction to HF was accompanied by a prevention of skeletal muscle atrophy that did not occur via an increase in anabolic factors, but through anti-catabolic activity, presumably caused by PGC1α action. These findings indicate the therapeutic potential of aerobic ET to block HF-induced muscle atrophy by counteracting the increased catabolic state.

材料
货号
品牌
产品描述

Sigma-Aldrich
甘油, ACS reagent, ≥99.5%
Sigma-Aldrich
甘油, for molecular biology, ≥99.0%
Sigma-Aldrich
甘油, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
十二烷基硫酸钠, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC)
Sigma-Aldrich
十二烷基硫酸钠, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
十二烷基硫酸钠 溶液, BioUltra, for molecular biology, 10% in H2O
Sigma-Aldrich
甘油 溶液, 83.5-89.5% (T)
Sigma-Aldrich
十二烷基硫酸钠 溶液, BioUltra, for molecular biology, 20% in H2O
Sigma-Aldrich
十二烷基硫酸钠, BioUltra, for molecular biology, ≥99.0% (GC)
Sigma-Aldrich
甘油, BioUltra, for molecular biology, anhydrous, ≥99.5% (GC)
Sigma-Aldrich
甘油, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
甘油, puriss., anhydrous, 99.0-101.0% (alkalimetric)
USP
甘油, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甘油, FCC, FG
Sigma-Aldrich
甘油, puriss. p.a., ACS reagent, anhydrous, dist., ≥99.5% (GC)
Sigma-Aldrich
十二烷基硫酸钠, ACS reagent, ≥99.0%
Supelco
十二烷基硫酸钠, dust-free pellets, suitable for electrophoresis, for molecular biology, ≥99.0% (GC)
Sigma-Aldrich
甘油, ≥99.5%
Sigma-Aldrich
十二烷基硫酸钠, ≥98.0% (GC)
Sigma-Aldrich
十二烷基硫酸钠, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
S-亚硝基-N-乙酰基-DL-青霉胺, ≥97%, powder
Sigma-Aldrich
溴酚蓝, ACS reagent
Sigma-Aldrich
溴酚蓝, titration: suitable
Sigma-Aldrich
甘油, BioXtra, ≥99% (GC)
Supelco
甘油, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
十二烷基硫酸钠, 92.5-100.5% based on total alkyl sulfate content basis
Sigma-Aldrich
十二烷基硫酸钠, tested according to NF, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate
Sigma-Aldrich
甘油 溶液, puriss., meets analytical specification of Ph. Eur., BP, 84-88%
Sigma-Aldrich
甘油, meets USP testing specifications
Sigma-Aldrich
十二烷基硫酸钠, BioXtra, ≥99.0% (GC)